Harnessing the power of science to make health happen.
To care, help and heal.
AstraZeneca (Thailand) Ltd (AZTH) was registered in Thailand in 1983 and is part of AstraZeneca, a global, science-led biopharmaceutical company which operates in over 100 countries, that focuses on the discovery, development, and commercialisation of prescription medicines. AZTH focus on leadership in three main therapy areas: Oncology, Cardiovascular, Renal and Metabolism (CVRM), Respiratory, Immunology, Vaccines and Immune Therapies (RIVIT). There are more than 20 medicines in the company portfolio, and over 1M patients take our medicines in Thailand on an annual basis. COVID-19 has created an unprecedented crisis over the last two years. This is particularly relevant in Thailand, as one and only manufacturing and supply hubs of AstraZeneca’s COVID-19 vaccine for Thailand and South East Asia.
AZTH has a bold vision to make health happen for the people of Thailand. From disease awareness, early diagnostics, improving the access and availability of innovative medicines alongside ensuring that we contribute to a sustainable environment. Over the last 40 years, the company have been committed to creating access to innovative medicines, improving access to healthcare and innovations to improve outcomes.
With their mission to be ‘inspired to change outcomes for patients, making health happen for Thai people’, AZTH is driven by science, building success across their markets and their therapy areas by continuing to create genuinely innovative medicines and improving access to them. Through this, they are able to deliver the greatest benefit to patients, healthcare systems and societies globally.
Guided by their values and behaviours, their people are empowered and inspired to thrive in an environment where they make a difference to patients, society and the company. They are committed to investing in these four key areas, which are enhancing their understanding of disease biology, discovering new ways to target the drivers of disease, better predicting clinical success and pioneering new approaches to patient engagement. AZTH believes these areas will help in their aspiration to create the greatest and swiftest impact on disease.
Being a leading pharmaceutical player in the industry, AZTH has been recognized on numerous occasions such as one of the Top Community Care Companies in Asia for outstanding work in the communities in Asia Corporate Excellence & Sustainability Awards (ACES) 2019. Most recently, AZTH has been recognized by The Top Employers Institute, as 2022 Top Employer in Thailand and Asia Pacific. Being certified as a Top Employer showcases the company’s dedication to a better world of work, exhibited through excellent staff-oriented policies, a life-long learning culture, and an diversity and inclusive workplace where employees can thrive and develop.
AZTH has also been ranked as the No.1 scientific leader among the pharmaceutical companies in Thailand by the latest market survey results, conducted by Ipsos Healthcare, a research company of published research and thought pieces available on topics related to the Healthcare sector.
In the survey, AZTH has been recognized by the Key External Experts (KEEs) across four therapy areas, including diabetes, respiratory, lung cancer and women’s cancer in Thailand from April to August 2021. The successful result is driven by strong scientific collaboration with medical societies, promising pipelines, research and development, therapeutic area expertise, and information presented at national and international congresses.
AZTH recognizes the importance of not only those environmental, social and governance (ESG) issues that impact their business, but also how their business impacts ESG matters. Gathering broad stakeholder input to help them refine their approach, it is through the open and transparent dialogues with their stakeholders that they uncover solutions to advance the health of people, the planet, and the society.
Their three interconnected sustainability priorities, which are access to healthcare, environmental protection, and ethics and transparency are underpinned by nine material focus areas where they can make the most impact. AZTH believes that integrating sustainability into everything that they do future-proofs their business to make it resilient in challenging times, helping ensure they can continue to deliver life-changing medicines to patients.
AZTH acknowledges that their people are their greatest asset, noting that their workforce are people who live and breathe their purpose of pushing the boundaries of science and delivering life-changing medicines. Through fostering an environment where their people feel they belong, employees are empowered to reach their full potential and perform at their best; setting themselves up to make the biggest possible difference to their patients, a meaningful contribution to society, and a positive impact on the planet.
While engaging in a life-long learning culture, employees are also encouraged to demonstrate inclusive leadership by speaking up and presenting fresh perspectives. As a company that values an innovative and collaborative culture, AZTH provides multiple avenues for their employees to improve themselves.
On the community front, AZTH has kept engagement with the community close to their hearts. AZTH, in collaboration with Plan International Thailand, drives the Young Health Programme (YHP), a global disease prevention programme focusing on young people that aims to prevent the most common non-communicable diseases (NCDs) such as cancer, diabetes, heart disease, respiratory disease, and mental ill health.
In line with the global YHP Theory of Change, the programme is implemented using four key inter-related and reinforcing strategies, which are empowering young people, mobilizing communities, strengthening health systems and advocating for policy change. This model ensures that AZTH is not just working with young people in isolation, but also strengthening the systems and structures in their environment, which contribute to their health and well-being.
Delivered in partnership with Plan International and UNICEF, and backed by research from the Johns Hopkins Bloomberg School of Public Health, YHP was founded in 2010 as AstraZeneca’s global community investment initiative; with their employees providing volunteer support for many of the programmes. The YHP in Thailand is a five-year programme that started in July 2019, and the achievements so far include Peer Educator Capacity Building Program, increase community knowledge and awareness on NCDs, social media campaign for the engagement of indirect beneficiaries, and strengthen youth-friendly health services.
For YHP Thailand, the direct beneficiaries of the program are 75,000 young people, aged between 10 and 24 years old, from the target districts in the Greater Bangkok area and Samutprakan. To name a few, from July 2019 – June 2022, it reached over 3.5 million young people and over 2.1 million adults on social media campaign. Additionally, it also reached 50,345 young people through Peer Educator and YHP school health programs, empowered 2,185 teachers through training, and reached 7,582 parents and caregivers through online and onsite learning sessions.
“AstraZeneca Thailand’s dedication to a better world of work, exhibited through excellent staff-oriented policies, a life-long learning culture, and an inclusive workplace where employees can thrive and develop makes it an organization worthy of ACES.”
Shanggari Balakrishnan, Chief Executive Officer, MORS Group
News Distribution Partner
Copyright 2023 MORS GROUP (1084230-V) | ACES AWARDS | All Rights Reserved